Neve Ativ

New Real-World Data Presented at OPTIONS XI Show Cell-Based and MF59®-Adjuvanted Influenza Vaccines Can Reduce the Burden of Seasonal Influenza on Hospitals and Health Systems

Retrieved on: 
Monday, September 26, 2022
Center, Delta, Exhibition, Bed, Society, Patient, Immunodeficiency, Pneumonia, CDC, Emergency, Stroke, Influenza vaccine, Research, Myocardial infarction, Disease, CSL Limited, QALY, MPH, CSL, RCT, ASX, Hospital, COVID-19, Selection bias, Knowledge, Antibody, Influenza, Doctor of Philosophy, Ageing, Observational study, RWE, Haemophilia, CSL Behring, Population, Degenerative disease, 2022–23 UEFA Nations League, Immunization, Neve Ativ, Vaccine, Public health, Korea Disease Control and Prevention Agency, Health, Incidence, Control, Vaccination, MF59, Impact, ICU, Meta-analysis, Randomized controlled trial, Death, Biotechnology, R, RVE, Omicron, MD

The data were presented at OPTIONS for the Control of Influenza XI (OPTIONS XI), being held in Belfast, United Kingdom, from September 26-29, 2022.

Key Points: 
  • The data were presented at OPTIONS for the Control of Influenza XI (OPTIONS XI), being held in Belfast, United Kingdom, from September 26-29, 2022.
  • RWE is a complement to randomized controlled trial (RCT) research, assessing influenza vaccine innovation effectiveness on a continual basis and providing an ever-growing data set on real-world outcomes.
  • Real-World Effectiveness of MF59-Adjuvanted Influenza Vaccine in Preventing Hospitalizationsin Adults 65 Years During the 2019-2020 U.S.
  • No difference was observed between the two types of vaccines in hospitalizations related to pneumonia, myocardial infarction or ischemic stroke.

New Data Supports the Effectiveness of Adjuvanted Seasonal Influenza Vaccine in Reducing Influenza-Related Hospitalizations and Healthcare Costs in Older Adults

Retrieved on: 
Tuesday, December 7, 2021
RWE, Risk, Influenza vaccine, Population, Hospital, Disease, CSL, Haemophilia, European Scientific Cooperative on Phytotherapy, Economy, VAERS, Vaccine, CSL Behring, Antibody, Muscle weakness, Allergy, World, Event-driven architecture, Health, Influenza, Patient, Life expectancy, Selection bias, ASX, MF59, Conference, CDC, World Health Organization, Pablo de Olavide University, R, Season, Ageing, Society, FDA, Vaccination, TIV, Guillain–Barré syndrome, Degenerative disease, Research, Biotechnology, Immune system, MD, Immunodeficiency, Neve Ativ, WHO, Health insurance, Pharmaceutical industry, Dietary supplement

Individual study limitations may include: retrospective analyses, a potential lack of laboratory confirmed influenza, and varying data sources.

Key Points: 
  • Individual study limitations may include: retrospective analyses, a potential lack of laboratory confirmed influenza, and varying data sources.
  • As one of the largest influenza vaccine providers in the world, Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness.
  • FLUAD (Influenza Vaccine, Adjuvanted) and FLUAD QUADRIVALENT (Influenza Vaccine, Adjuvanted)
    What are FLUAD and FLUAD QUADRIVALENT?
  • To learn more, talk about FLUAD and/or FLUAD QUADRIVALENT with your healthcare provider or pharmacist.

Seqirus Presents New Real-World Evidence Supporting Effectiveness of Differentiated Seasonal Influenza Vaccine Technologies at ISIRV-WHO Virtual Conference 2021

Retrieved on: 
Tuesday, October 19, 2021
ASX, Cohort study, Immune system, Allergy, WHO, Influenza, CDC, Death, MD, RWE, COVID-19, RVE, Pharmacy, Antibody, Centre de coopération internationale en recherche agronomique pour le développement, Guillain–Barré syndrome, Doctor of Philosophy, TNT, Ageing, Disease, Haemophilia, Muscle weakness, International Society, Vaccine, Selection bias, CSL Behring, Vaccination, R, Event-driven architecture, Patient, Conference, Neve Ativ, CSL, Adult, Population, Immunodeficiency, Degenerative disease, Health, Hospital, Health insurance

SUMMIT, N.J., Oct. 19, 2021 /PRNewswire/ -- Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced new real-world evidence (RWE) supporting the effectiveness of its cell-based and adjuvanted seasonal influenza vaccines.

Key Points: 
  • SUMMIT, N.J., Oct. 19, 2021 /PRNewswire/ -- Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced new real-world evidence (RWE) supporting the effectiveness of its cell-based and adjuvanted seasonal influenza vaccines.
  • "These retrospective studies, which include over 10 million vaccinated U.S. individuals, build on existing RWE in evaluating the effectiveness of influenza vaccines in real-world settings.
  • "These data support that our vaccines can help reduce IRMEs and minimize the burden of influenza, among children and older populations."
  • As one of the largest influenza vaccine providers in the world, Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness.

Seqirus Presents New Real-World Evidence Demonstrating Effectiveness of Cell-Based and Adjuvanted Seasonal Influenza Vaccines at IDWeek 2021

Retrieved on: 
Wednesday, September 29, 2021
Vaccination, RWE, Immunodeficiency, Vaccine, Pressure, Muscle weakness, RVE, Neve Ativ, CSL, Hospital, Patient, Allergy, Adjuvant, MD, Influenza, Guillain–Barré syndrome, CDC, Immune system, CSL Behring, Selection bias, Antibody, Ageing, Disease, ASX, Risk, Degenerative disease, Population, Haemophilia, R, Safety, Investment, Doctor of Philosophy

These analyses will be presented today at the virtual IDWeek 2021 conference.

Key Points: 
  • These analyses will be presented today at the virtual IDWeek 2021 conference.
  • "These data further underscore the public health benefits of innovative technologies, including cell-based and adjuvanted technologies, in producing seasonal influenza vaccines."
  • "We continue making critical R&D investments to measure how our influenza vaccines perform in real-world settings and to advance next-generation technology platforms thathelp safeguard people and communities from influenza."
  • As one of the largest influenza vaccine providers in the world, Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness.